source
- FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failureThe U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
- nChroma Bio halts sole clinical trial and cuts staff by halfTwo Boston-area biotech founders merged their companies a few years ago to create nChroma Bio, hoping the combined effort would weather a weak market for genetic‑medicine firms. The company has no…